#Lipogems
LightNews LightNews
newsen.bsky.social
Lipogems Celebrates Milestone in ARISE I Knee Osteoarthritis Clinical Trial Completion#United_States#Atlanta#Osteoarthritis#Lipogems#Medical_Trials
Lipogems Celebrates Milestone in ARISE I Knee Osteoarthritis Clinical Trial Completion
Lipogems proudly announces the successful completion of the ARISE I clinical trial for knee osteoarthritis, paving the way for innovative treatments.
third-news.com
May 7, 2025 at 1:48 PM
newsen.bsky.social
Lipogems Completes Enrollment for Groundbreaking Knee Osteoarthritis Clinical Trial#United_States#Atlanta#Lipogems#Knee_Osteoarthritis#ARISE_II
Lipogems Completes Enrollment for Groundbreaking Knee Osteoarthritis Clinical Trial
Lipogems has successfully enrolled the final patient in the ARISE II trial, focusing on knee osteoarthritis treatments and evaluating MicroFat injections.
third-news.com
March 5, 2025 at 3:11 PM
fasciainstitute.bsky.social
📧 FIT November Highlights

✔️ FIT Research: Dr. Courseault featured at
AAPM&R.
✔️ Lipogems ARISE II Study: See if you qualify!
✔️ Relief: Hydrofascial Release™ boosts mobility.
✔️ #Hypermobility: Could be #EDS—get care early!

📬 Read more: bit.ly/4fH8iaH #wellness
November 21, 2024 at 8:42 PM
l2plabs.bsky.social
LIPOGEMS ANNOUNCES LAST PATIENT LAST VISIT FOR ARISE 1 KNEE OSTEOARTHRITIS TRIAL
ATLANTA, May 7, 2025 /PRNewswire/ -- Lipogems is proud to announce the completion of the ARISE I U.S. FDA IDE Study with the last patient's last visit successfully completed. This milestone marks the conclusion of a key phase in the advancement of Lipogems for the treatment of knee...
dlvr.it
May 7, 2025 at 1:26 PM
l2plabs.bsky.social
LIPOGEMS ANNOUNCES ENROLLMENT OF THE FINAL PATIENT IN ARISE FDA CLINICAL TRIALS FOR KNEE OSTEOARTHRITIS
ATLANTA, March 5, 2025 /PRNewswire/ -- Lipogems has announced the final patient enrolled in the ARISE II U.S. FDA IDE Study, which aims to evaluate the efficacy and safety of MicroFat injections compared to saline for the treatment of Knee Osteoarthritis…
dlvr.it
March 5, 2025 at 3:19 PM